WO1990011356A1 - Expression vector, eukaryotic cells and method for the recovery of pdgf-aa - Google Patents
Expression vector, eukaryotic cells and method for the recovery of pdgf-aa Download PDFInfo
- Publication number
- WO1990011356A1 WO1990011356A1 PCT/EP1990/000440 EP9000440W WO9011356A1 WO 1990011356 A1 WO1990011356 A1 WO 1990011356A1 EP 9000440 W EP9000440 W EP 9000440W WO 9011356 A1 WO9011356 A1 WO 9011356A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pdgf
- vector
- cells
- cell
- expression vector
- Prior art date
Links
- 108010017843 platelet-derived growth factor A Proteins 0.000 title claims abstract description 43
- 239000013604 expression vector Substances 0.000 title claims abstract description 12
- 210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 19
- 238000011084 recovery Methods 0.000 title claims description 5
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 6
- 239000005373 porous glass Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229910010293 ceramic material Inorganic materials 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 238000004007 reversed phase HPLC Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000578786 Leishmania major Membrane antigen containing repeating peptides Proteins 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000012786 cultivation procedure Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
Definitions
- Expression vector eukaryotic cells and method for the recovery of PDGF-AA.
- Platelet Derived Growth Factor 9PDGF0 is a principal mitogen in the serum which promotes the growth of fibroblasts and smooth muscle cells in vitro.
- PDGF is stored in the alpha granules of the thrombocytes and released by stimulation of the thrombocytes.
- Highly purified PDGF is a basic protein which has considerable heterogeneity in its molecular weigth (Kb 27,000 to 31,000 d). The reasons for this heterogeneity are age, processing, and the existence of various isoforms of type AA, AB or BB. The biological activity of all these forms is destroyed by reduction of the disulfide bridges.
- Human PDGF from thrombocytes consists mainly of AB heterodimers; cf. (Heldin & Westermark 198 , Deuel et al. 1985, and Ross et al. 1986).
- PDGF-B is virtually identical with the transforming gene product p28 of Simian Sarcoma Virus (SSV).
- SSV Simian Sarcoma Virus
- BB homodimers of type BB
- BB d i mer s were secreted to only a small extent from the infected cells.
- PDGF-AA forms were efficiently secreted by producing cells. There are an increasing number of indications that the three isoforms, AA, AB and BB, take care of different functions. For detailed research, therefore it was necessary to develop a new teaching whereby larger amounts of PDGF-AA can be obtained.
- an expression vector is provided for the recovery of PDGF-AA with the following features:
- the hybridizable DNA range can be hybridized at at least 20°C and especially at least 25°C and /or a sodium chloride concentration of 1M.
- the above-mentioned DNA Range can be synthesized by means of a DNA synthesizer or on a bioengi neering route as follows.
- eukaryotic cells are provided for the recovery of PDGF-AA which are obtainable by chromosomal integration of the vector of the invention by the method of Wigler et al.; cf Cells, 16 (1979) 777-785.
- An example of a cell suitable for the integration is BHK-21
- a method for the expression of PDGF-AA is provided, which is characterized in that
- a vector in accord with the invention is chromosomany integrated into a eukaryotic cell by the method of Wigler, Sweet, Sim, Wold, Pellicer, Lacy, Maniatis, Silverstein & Axel and
- a eukariotic cell containing a vector according to the invention is cultivated and PDGF-AA is expressed.
- BHK-21 (ATCC-CCL 10; U.S. Patent 4,049,494); Organon, OSS,
- PDGF-AA can, according to an additional embodiment of the invention, especially when it has been expressed by the method of the invention, can be processed from aqueous media, especially expression cultures, by adsorbing the PDGF-AA onto a ceramic material, such as glass, for example, especially porous glass.
- PDGF-AA can be eluted and then subjected to a gel permeation chromatography and/or a reverse-phase HPLC chromatography.
- the i nventi on wi l l be expl ai ned be l ow by experi ment al d at a and 3 f i gures
- Insert Mature sequence of the rPDGF-AA expressed from BHK cells.
- A alanine
- D aspartic acid
- E glutamic acid
- F phenyl- alanine
- G glycine
- H histidine
- I isoleucine
- K lysine
- L leucine
- M methionine
- N asparagine
- P proline
- Q glutamine
- R arginine
- S serine
- T threonine
- V valine
- W trypthophan
- Y tyrosine.
- the samples were separated on a 15 % polyacryl amide gel in the presence of SDS and analyzed after Coomassie blue dyeing.
- E-H Same application series as A-D, with the addition of 10 % mercaptcethanol (10', 100 °C) in each case.
- the detection of biological activity was performed by stimulating densely arrested mouse embryo cells (AKR-2B) for synthesis of DNA (Shipley et. al. 1984)
- Porous glass PG 120-200, Sigma; Bio-Gel B100, 200-400 mesh, Bio- Rad; modified silica gel 214 Tp 54, 10 ⁇ m ( Vydac C4) by Vydac (Macherey & Nagel); urea by Sigma.
- Ethylene glycol and buffers were from Merck. Restriction endonucl eases and ligases were ordered from Boehringer and BRL, respectively.
- PDGF-AA was able to be purified to homogeneity from supernatant fluids of these cell cultures by a three-stage process.
- the first step was adsorption onto porous glass, the second step gel permeation chromatography on Bio-Gel P100.
- the final purification was achieved by reverse-phase high- pressure liquid chromatography.
- the yields were approximately 0.2 mg PDGF-AA/1 of supernatant liquid from the cell culture.
- the specific activity was 4 ng/ml for 50% activation of the ( 3 H) thymidine installed in AKR-2B mouse fi brobl asts
- PDGF-A a fragment 712 base pairs long was obtained by Rsal digestion, which likewise still contains the entire coding range. This fragment was integrated into the Smal intersection in the polylinker of the plasmid pBEH. The orientation was determined by SalI cleavage. A plasmid was obtained which contained the PDGF-A gene in the correct orientation under the control of the SV 40 promoter in the plasmid pBEH. This plasmid was named pODa.
- the transfection of BHK21 cells was performed substantially by the method of Wigler et al., 1979.
- the cells to be transfected were abtrypsinated in the exponential growth phase before reaching confluence, counted, reseeded in a cell density of 3 x 10 5 cells per culture bottle (25 cm 2 bottom area) in 5 ml of culture medium and incubated for 24 h at 37°C. On the following day, 4 hours before adding the precipitates, the medium was removed and replaced with fresh culture medium.
- the precipitates were prepared as follows: 5 ⁇ g of the DNS (pODa) to be transformed were dissolved under sterile conditions together with 5 ⁇ g carrier DNS from LTK cells with 5 ⁇ g of selection DNS (pAG 60, Bam HI cut) in 0.25 ml of 250 mM CaCl 2 . This solution was added slowly, drop by drop, with constant agitation by air injected through a cottonstuffed Pasteur pipette, to 250 ⁇ l of 2 x HEBS buffer (280mM NaCl, 50 mM HEPES, 1.5 nM NaH 2 PO 3 , pH 7.1), resulting in the formation of a DNS/calcium phosphate coprecipitate.
- the solution thus prepared was incubated for an another hour at room temperature for complete precipitation, and then added to the cultures to be transfected. After 16 h the medium was replaced with fresh culture medium. On the second day after addition of the precipitates selection began by replacing the medium with fresh culture medium to which 500 ⁇ g/ml of G 418 were added. The selection medium was renewed eve ry 2-3 days. After 2 to 4 weeks, 2000 colonies were recognizable. To select for a stable transformation the cells were given tow passages in selection medium. These colonies were combined and recloned by limit dilution. Some clones were tested for their productivity on PDGF-AA. A high producer (clone 39) was obtained.
- the elution was performed through a linear gradient of 14 % acetonitrile in 0.1 % trifluoroacetic acid/H 2 O for 70 minutes at a rate of flow of 0.7 ml per minute.
- the extinction at 220 nm was continously recorded and fractions of 0.7 ml were collected.
- PDGF-AA eluted at an acetronitrile content of 26-27 % . Aliquots of the fractions were tested by gel electrophoresis and those containing no foreign protein were combined.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to expression vectors and a method for production of PDGF-AA in eukaryotic cells. The expression vector comprises a DNA sequence encoding PDGF-A, under the control of an SV40 promoter. The expression vectors are used in eukaryotic, particularly mammalian cells to produce PDGF in large quantities.
Description
Expression vector, eukaryotic cells and method for the recovery of PDGF-AA.
Platelet Derived Growth Factor 9PDGF0 is a principal mitogen in the serum which promotes the growth of fibroblasts and smooth muscle cells in vitro. In vivo, PDGF is stored in the alpha granules of the thrombocytes and released by stimulation of the thrombocytes. Highly purified PDGF is a basic protein which has considerable heterogeneity in its molecular weigth (Kb 27,000 to 31,000 d). The reasons for this heterogeneity are age, processing, and the existence of various isoforms of type AA, AB or BB. The biological activity of all these forms is destroyed by reduction of the disulfide bridges. Human PDGF from thrombocytes consists mainly of AB heterodimers; cf. (Heldin & Westermark 198 , Deuel et al. 1985, and Ross et al. 1986).
Amino acid sequencing in conjunction with DNA sequencing of the genes has shown that A and B are homologous. PDGF-B is virtually identical with the transforming gene product p28 of Simian Sarcoma Virus (SSV). In SSV-transformed cells corresponding homodimers of type BB have been detected, which displayed propert i es s i mi l ar to tho se of th rombocyti c PDGF . These BB d i mer s were secreted to only a small extent from the infected cells. PDGF-AA forms, however, were efficiently secreted by producing cells.
There are an increasing number of indications that the three isoforms, AA, AB and BB, take care of different functions. For detailed research, therefore it was necessary to develop a new teaching whereby larger amounts of PDGF-AA can be obtained.
According to one embodiment of the invention, an expression vector is provided for the recovery of PDGF-AA with the following features:
- SV40 promoter and
- DNA range which is controlled by the said promoter and codes PDGF-AA of the following amino acid sequence:
SIEEAVPAVCKTRTVIYEIPRSQVDPTSAN FLIWPPCVEVKRCTGCCNTSSVKCOPSRVH HRSVKVAKVEYVRKKPKLKEVQVRLEEHLE
CACATISLNPDYREEDTDVR
or a DNA range of about the same number of base triplets which can be hybridized with the above DNA range.
The hybridizable DNA range can be hybridized at at least 20°C and especially at least 25°C and /or a sodium chloride concentration of 1M. The above-mentioned DNA Range can be synthesized by means of a DNA synthesizer or on a bioengi neering route as follows. According to a further embodiment of the invention, eukaryotic cells are provided for the recovery of PDGF-AA which are obtainable by chromosomal integration of the vector of the invention by the method of Wigler et al.; cf Cells, 16 (1979) 777-785.
An example of a cell suitable for the integration is BHK-21
(ATCC-CCL 10).
According to an additional embodiment of the invention a method for the expression of PDGF-AA is provided, which is characterized in that
(al) a vector in accord with the invention is chromosomany integrated into a eukaryotic cell by the method of Wigler, Sweet, Sim, Wold, Pellicer, Lacy, Maniatis, Silverstein & Axel and
(a2) the cell obtained according to (al) is cultivated and PDGF- AA is expressed, or
(b) a eukariotic cell containing a vector according to the invention is cultivated and PDGF-AA is expressed.
BHK-21 (ATCC-CCL 10; U.S. Patent 4,049,494); Organon, OSS,
Netherlands; ECACC, Portandown Great Britain), for example, is suitable for the practice of the method of the invention.
PDGF-AA can, according to an additional embodiment of the invention, especially when it has been expressed by the method of the invention, can be processed from aqueous media, especially expression cultures, by adsorbing the PDGF-AA onto a ceramic material, such as glass, for example, especially porous glass.
In addition to the above-described processing, the adsorbed
PDGF-AA can be eluted and then subjected to a gel permeation chromatography and/or a reverse-phase HPLC chromatography.
The i nventi on wi l l be expl ai ned be l ow by experi ment al d at a and 3 f i gures
F i g . 1
Construction of the pODa Expression Vector
An Rsal cleavage product of the c-DNS clone pPFa-1 which includes the entire precursor molecule of the PDGF-A chain was cloned "blund ends" into the Smal cleavage point of the SV40 expression vector pBEH where it is under the control of the SV40 "early" promoter and of the SV 40 "late" polyadenyl ati on sequence. The vectors are not represented in correct scale to one another.
Insert: Mature sequence of the rPDGF-AA expressed from BHK cells. A = alanine, D = aspartic acid, E = glutamic acid, F = phenyl- alanine, G = glycine, H = histidine, I = isoleucine, K = lysine, L = leucine, M = methionine, N = asparagine, P = proline, Q = glutamine, R = arginine, S = serine, T = threonine, V = valine, W = trypthophan, Y = tyrosine.
Fig. 2
Purification of rPDGF-A from supernatant liquors on cultures of transformed BHK CELLS (Subclone 39)
The samples were separated on a 15 % polyacryl amide gel in the presence of SDS and analyzed after Coomassie blue dyeing.
A = Conditioned culture supernatant liquor (fermentation)
B = Eluate CPG chromatography
C = Eluate P 100 chromatography
D = Purified PDGF-A after HPLC
E-H = Same application series as A-D, with the addition of 10 % mercaptcethanol (10', 100 °C) in each case.
Fig. 3
Biological activity of rPDGF-AA from BHK cells.
The detection of biological activity was performed by stimulating densely arrested mouse embryo cells (AKR-2B) for synthesis of DNA (Shipley et. al. 1984)
Live Material used Reference
SV40 Promoter and Vector
with SV40 Promoter Pharmacia pPFa-1 = pPFG-1 FEBS Lett., 223 (1987)
243-246 pBEH Gene, 68 (1988) 213-219 pAG60 AKR-28 Example for mouse fibroblasts BHK 21 ATCC-CCL 10 LTK
Material and Methods
Cells cultures supplied by Gibco. Chromatography materials:
Porous glass PG 120-200, Sigma; Bio-Gel B100, 200-400 mesh, Bio- Rad; modified silica gel 214 Tp 54, 10 μm (=Vydac C4) by Vydac (Macherey & Nagel); urea by Sigma. Ethylene glycol and buffers were from Merck. Restriction endonucl eases and ligases were ordered from Boehringer and BRL, respectively.
Analytic Methods
Growth promoting activity was analyzed according to Shipley et al. (1984) by determining the (3H) thymidine rate in density- arrested mouse AKR-2B fibroblasts. Protein content was determined according to Bradford. Ami notermi nal sequence analysis was performed by means of a gas-liquid phase protein sequenator (Applied Biosystems). PTH amino acids were determined "on line" by HPLC chromotography. Polyacryl amide gel electrophoresis in the presence of sodium dodecyl sulfate was performed as described (Hoppe et al., 1986). Standard DNA techniques were performed according to Maniatis (1982).
SUMMARY
An Rsal fragment 712 base pairs long from the vector pPFa-1 (= pPGF-1) (Hoppe et al. 1987), containing the range coding PDGF-A, was integrated into the Smal intersection of the SV40 expression vector pBEH (Artel et al. 1988) and thus brought under the control of the SV40 promoter. This plasmid was integrated with chromosomes stable into BHK21 cells by cotransfer with the plasmid pAG60 (Colbere-Garapin et al., 1988). After subclonation a cell line was obtained which secreted up to 1 mg/1 of PDGF-AA/day into the nutrient medium. PDGF-AA was able to be purified to homogeneity from supernatant fluids of these cell cultures by a three-stage process. The first step was adsorption onto porous glass, the second step gel permeation chromatography on Bio-Gel P100. The final purification was achieved by reverse-phase high- pressure liquid chromatography. The yields were approximately 0.2 mg PDGF-AA/1 of supernatant liquid from the cell culture. The specific activity was 4 ng/ml for 50% activation of the (3H) thymidine installed in AKR-2B mouse fi brobl asts
Example
Construction of the Expression Vector pODa
From the 1.2 Kb long Bam HI fragment of the plasmid pPFa-1 (Hoppe et al., 1987), which contains the complete coding range for
PDGF-A, a fragment 712 base pairs long was obtained by Rsal digestion, which likewise still contains the entire coding range.
This fragment was integrated into the Smal intersection in the polylinker of the plasmid pBEH. The orientation was determined by SalI cleavage. A plasmid was obtained which contained the PDGF-A gene in the correct orientation under the control of the SV 40 promoter in the plasmid pBEH. This plasmid was named pODa.
Transfection of BHK21 cells
The transfection of BHK21 cells was performed substantially by the method of Wigler et al., 1979. The cells to be transfected were abtrypsinated in the exponential growth phase before reaching confluence, counted, reseeded in a cell density of 3 x 105 cells per culture bottle (25 cm2 bottom area) in 5 ml of culture medium and incubated for 24 h at 37°C. On the following day, 4 hours before adding the precipitates, the medium was removed and replaced with fresh culture medium. The precipitates were prepared as follows: 5 μg of the DNS (pODa) to be transformed were dissolved under sterile conditions together with 5 μg carrier DNS from LTK cells with 5 μg of selection DNS (pAG 60, Bam HI cut) in 0.25 ml of 250 mM CaCl2. This solution was added slowly, drop by drop, with constant agitation by air injected through a cottonstuffed Pasteur pipette, to 250 μl of 2 x HEBS buffer (280mM NaCl, 50 mM HEPES, 1.5 nM NaH2PO3, pH 7.1), resulting in the formation of a DNS/calcium phosphate coprecipitate. The solution thus prepared was incubated for an another hour at room temperature for complete precipitation, and then added to the cultures to be transfected. After 16 h the medium was replaced with fresh
culture medium. On the second day after addition of the precipitates selection began by replacing the medium with fresh culture medium to which 500 μg/ml of G 418 were added. The selection medium was renewed eve ry 2-3 days. After 2 to 4 weeks, 2000 colonies were recognizable. To select for a stable transformation the cells were given tow passages in selection medium. These colonies were combined and recloned by limit dilution. Some clones were tested for their productivity on PDGF-AA. A high producer (clone 39) was obtained.
Cultivation of Cells and Isolation of PDGF-AA
To obtain larger amounts of supernatant liquors from cell cultures, cells of clone 39 were cultivated in 15 roller bottles
(600 cm2 area, Falcon) in HG-DMEM/10% FCS, 25 mM HEPES, pH 7.4 (37ºC). Afterreaching confluence the cells were twice washed with HG-DMEM, 25 mM HEPES, and kept in this medium for 2 days. Then they were cultivated for 12 hours in HG-DMEM, 25 nM HEPES, 10 % FCS. This procedure was carried on for 4 weeks. A total of about 25 liters of supernatant liquors were obtained. Proteins from the combined supernatant liquors were all absorged onto CPG 120-200 prorous glass. For this purpose, 1 % w/v of glass was added to the liquor and incubated for 1/2 h. CPG glass was collected in a column (5cm0) and the liquors were again filtered through the CPG glass. Then a washing was performed with 10 mM of sodium phosphate, 0.5 M NaCl buffer, pH 7.2, until the OD280 (1cm) had dropped below 0.005. The elution of PDGF-AA was
achieved with 0.4 M glycine/HCL, pH 2.0, 6 % urea, 6 % ethylene glycol. After the dialysis of fractions containing PDGF-AA against 10mM of sodium phosphate, pH 7.5, precipitation was performed by adding 80 % ammonium sulfate (saturation). The precipitate was dissolved in the smallest possible volume of 10mM acetic acid. 10 ml portions were applied to a column 2cm∅ x 140 cm (Bio-Gel P 100 in 0.1 M acetic acid. The rate of flow was about 15 ml/h. Fractions of 4 ml were collected. Aliquots of the fractions were analyzed by SDS gel el ectrophoresis. Fractions containing PDGF-AA were combined and placed on a Vydac C4 column (0.8 cm ∅ x 25 cm). The flow rate was 1 ml/min. The column had been balanced beforehand in 0.1 % trifluoroacetic acid. The elution was performed through a linear gradient of 14 % acetonitrile in 0.1 % trifluoroacetic acid/H2O for 70 minutes at a rate of flow of 0.7 ml per minute. The extinction at 220 nm was continously recorded and fractions of 0.7 ml were collected. PDGF-AA eluted at an acetronitrile content of 26-27 % . Aliquots of the fractions were tested by gel electrophoresis and those containing no foreign protein were combined.
RESULTS
The transfection of BHK21 cells with the vector pODa yielded 2000 independent clones. By recloning, strains were obtained which differed greatly in the production of PDGF-AA. Clones were ob
tained which under optimum conditions had as much as 1 mg/l of PDGF-AA in the supernatant liquor of the culture. One of these clones (clone 39) was further characterized.
By a simple cultivation procedure in roller bottles, 25 liters of supernatant liquor were obtained. The adsorption of the proteins on the porous glass proved to be optimal, both as regards the efficient reduction of a large volume of 25 1 to 250 ml, and as regards the theoretical yield of activity. A 5-fold concentration was achieved. By two additional chromatographic steps (gel permeation chromatography followed by reverse-phase high-pressure liquid chromatography) PDGF-AA was obtained in an approximately 50 % yield. About 0.2 mg of PDGF-AA was isolated from one liter of supernatant liquor. The material thus obtained is uniform in the SDS gel eletrocphoresis (Fig. 2) and in the aminoterminal sequence analysis it showed only the expected sequence SIEE. It is accordingly identified unequivocally as PDGF-AA. This material stimulated the installation of (3H) thymidine in densely arrested mouse fibroblasts AKR-2B semimaximal at a concentration of 5 ng/ml.
LITERATURE
Artelt, P., Morelle, C, Ausmeier, M., Fritzek, M., and Ηauser, H. (1988) Gene 68 , 213-219.
Bradford, M. J. (1976) Anal . Biochem. 72, 248-253.
Colbere-Garapin et al . (1981) J. Mol . Biol . 150, 1-14.
Hoppe, J., Gatti, D., Weber, H. and Sebald, W. (1986) Eur. J. Biochem. 155, 259-264.
Hoppe, J. Schumacher, L. , Eichner, W. and Weich, H. A. (1987) FEBS Lett. 223, 243-246.
Maniatis, T., Fritsch, E . F. and Sambrook, J. (1982) in:
Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory, New York.
Shipley, G. C, Childs, C. B., Volkenant, M. E. and Moses, H. L, (1984) Cancer Res. 44, 710-716
Wigler, M., Sweet. R., Sim, G.K. , Wold, B., Pellicer, A. , Lacy, E., Maniatis, T., Silverstein, S. and Axel, R. (1979) Cell 16, 777-785
PURIFICATION OF rPDGF-A FROM SUPERNATANT LIQUORS
(PROCESSING SCHEDULE)
24,7 l Conditioned Medium
at 4 °C applied to
250 ml Controlled pore glass
Wash with 10 mM sodium phosphate buffer (pH 7.1), 0.5 M NaCl, elute with 0.4 M glycine/HCl (pH 2.0), 6% urea, 6% ethylene glycol, dialyze against 10 mM sodium phosphate buffer (pH 7.5)
9.2 mg Ammonium sulfate precipitation
Add ammonium sulfate (80% saturation), dissolve sediment in 10 mM acetic acid, centrifuge and discard the pellet, reduce volume in vacuum concentrator
6.4 mg Gel filtration
Chromatograph on P-100 column, combine fractions containing PDGF
5 mg Reversed-phase HPCL
Claims
1. Expression vector for obtaining PDGF-AA with the following features:
- SV40 Promoter and
- DNA range which is controlled by the said promoter and codes PDGF-A of the following amino acid sequence:
SIEEAVPAVCKTRTVIYEIPRSQVDPTSAN FLIWPPCVEVKRCTGCCNTSSVKCOPSRVH HRSVKVAKVEYVRKKPKLKEVQVRLEEHLE CACATISLNPDYREEDTDVR
or a DNA range of approximately the same number of base triplets which can be hybridized with the said DNA range.
2. Expression vector of claim 1, characterized in that the hybridizable DNA range is hybridizable at at least 20 and especially at least 25°C and/or a sodium chloride concentration of 1M.
Eukaryotic cells for the recovery of PDGF-AA, obtainable by chromosomal integration of the vector of claim 1 or 2 by the method of Wigler, Sweet, Sim, Wold, Pellicer, Lacy, Maniatis, Silverstein & Axel.
Cells of claim 3, characterized in that the vector is integrated in BHK-21 (ATCC-CCL 10).
Method for the expression of PDGF-AA, characterized in that (al) a vector of claim 1 or 2 is integrated chromosomally into a eurkarytic cell by the method of Wigler, Sweet, Sim, Wold, Pellicer, Lacy, Maniatis, Silverstein & Axel, and (a2) the cell obtained according to (al) is cultivated and PDGF-AA is expressed, or
(b) a eurkariotic cell of claim 3 or claim 4 is cultivated and PDGF-AA is expressed.
Method of claim 5, steps (al) to (a2), characterized in that BHK-21 (ATCC-CCL 10) is used.
Method for the processing of PDGF-AA, especially that obtained in accordance with claim 5 or 6 from aqueous media, especially expression cultures, characterized in that PDGF- AA is adsorbed onto a ceramic material.
Method of claim 7, characterized in that glass, especially porous glass, is used as ceramic material.
9. Method of claim 7 or 8, characterized in that additionally the adsorbed PDGF-AA is eluted and then subjected to a gel permeation chromotography and/or to reverse-phase HPLC chromotography.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19893908802 DE3908802C2 (en) | 1989-03-17 | 1989-03-17 | Process for obtaining PDGF-AA |
DEP3908802.2 | 1989-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990011356A1 true WO1990011356A1 (en) | 1990-10-04 |
Family
ID=6376589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1990/000440 WO1990011356A1 (en) | 1989-03-17 | 1990-03-16 | Expression vector, eukaryotic cells and method for the recovery of pdgf-aa |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE3908802C2 (en) |
WO (1) | WO1990011356A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0288307A2 (en) * | 1987-04-22 | 1988-10-26 | Chiron Corporation | Recombinant production of PDGF A-chain polypeptides |
-
1989
- 1989-03-17 DE DE19893908802 patent/DE3908802C2/en not_active Expired - Lifetime
-
1990
- 1990-03-16 WO PCT/EP1990/000440 patent/WO1990011356A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0288307A2 (en) * | 1987-04-22 | 1988-10-26 | Chiron Corporation | Recombinant production of PDGF A-chain polypeptides |
Non-Patent Citations (4)
Title |
---|
Cell, Volume 16, 1979, M. WIGLER et al.: "Transformation of Mammalian Cells with Genes from Procaryotes and Eucaryotes", pages 777-785 * |
Eur. J. Biochem., Volume 185, 1989, W. EICHNER et al.: "Large-Scale Preparation of Recombinant Plateletderived Growth Factor AA Secreted from Recombinant Baby Hamster Kidney Cells", pages 135-140 * |
Febs Letters, Volume 223, No. 2, November 1987, Elsevier Publishers B.V., J. HOPPE et al.: "The Long 3'-Untranslated Regions of the PDGF-A and -B mRNAs are only Distantly Related", pages 243-246 * |
Gene, Volume 68, 1988, Elsevier Science Publishers B.V., P. ARTELT et al.: "Vectors for Efficient Expression in Mammalian Fibroblastoid, Myeloid and Lymphoid Cells via Transfection or Infection", pages 213-219 * |
Also Published As
Publication number | Publication date |
---|---|
DE3908802A1 (en) | 1990-09-20 |
DE3908802C2 (en) | 1994-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU645539B2 (en) | A recombinant human factor VIII derivative | |
KR0184235B1 (en) | A megakaryocytopoietic factor | |
US6777205B1 (en) | Host cells expressing recombinant human erythropoietin | |
JP4293908B2 (en) | Chromatographic purification of recombinant human erythropoietin | |
EP1707634A1 (en) | Method for isolation of recombinantly produced proteins | |
US6376218B1 (en) | Expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof | |
CA2704598A1 (en) | Methods of purifying recombinant human erythropoietin from cell culture supernatants | |
CN108610398A (en) | One section of functional sequence and the application in secretory protein expression | |
EP0316933A2 (en) | A process for producing apoaequorin | |
CA2252986A1 (en) | Process for preparing functional recombinant tissue factor | |
JP2010213699A (en) | Host cell expressing recombinant human erythropoietin | |
EP3075740B1 (en) | Method for purifying darbepoetin alfa | |
US11299548B2 (en) | Gene combination capable of high-efficiency expression of recombinant human nerve growth factor | |
CN104379598B (en) | Long-acting human growth hormone's albumen of high glycosylation and its production method | |
WO1990011356A1 (en) | Expression vector, eukaryotic cells and method for the recovery of pdgf-aa | |
KR101460266B1 (en) | A novel method for purifying long-acting human growth hormone | |
ES2315023T3 (en) | METHOD FOR THE MASSIVE CULTURE OF RECOMBINANT HUMAN ERYTHROPOYETIN CELLS. | |
US6399744B1 (en) | TCF mutant | |
CA2148935A1 (en) | Purification of fusion proteins comprising gm-csf and il-3 | |
TW570977B (en) | An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof | |
CN112195194A (en) | Recombinant human follicle stimulating hormone and preparation method thereof | |
WO2003046160A2 (en) | Methods of increasing protein expression levels | |
CZ34797A3 (en) | Process for preparing soluble recombinant proteins from bacterial cells | |
CA2144576A1 (en) | A single step purification of recombinant human interleukin-5 | |
BRPI0610958A2 (en) | method for producing a bioengineered form of tissue plasminogen activator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |